Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNASDAQ:CGEMNASDAQ:CTNMNASDAQ:SAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$5.30-2.4%$5.08$3.55▼$11.16$429.87M1.132.81 million shs2.50 million shsCGEMCullinan Therapeutics$8.75+1.2%$7.87$6.85▼$24.76$516.38M-0.07575,300 shs435,478 shsCTNMContineum Therapeutics$4.43+21.0%$4.51$3.35▼$22.00$114.61MN/A83,395 shs154,936 shsSAGESage Therapeutics$6.62+2.5%$7.11$4.62▼$13.47$414.55M0.21.19 million shs845,151 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-2.39%-7.18%-8.15%-11.07%-29.43%CGEMCullinan Therapeutics+1.04%+12.04%-0.46%+7.63%-62.77%CTNMContineum Therapeutics+22.38%+24.09%+8.05%-29.12%-71.08%SAGESage Therapeutics+1.85%+1.38%-9.32%-9.56%-40.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.3307 of 5 stars3.51.00.00.02.03.30.6CGEMCullinan Therapeutics2.3846 of 5 stars3.52.00.00.02.81.70.6CTNMContineum Therapeutics2.3407 of 5 stars3.62.00.00.03.20.80.6SAGESage Therapeutics3.5242 of 5 stars3.01.00.04.01.51.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 3.00Buy$20.20281.13% UpsideCGEMCullinan Therapeutics 3.00Buy$32.00265.71% UpsideCTNMContineum Therapeutics 3.20Buy$22.50407.90% UpsideSAGESage Therapeutics 2.06Hold$8.8733.94% UpsideCurrent Analyst Ratings BreakdownLatest CTNM, ALT, SAGE, and CGEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CTNMContineum TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$25.00 ➝ $20.005/15/2025CTNMContineum TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.005/12/2025CGEMCullinan TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $24.004/25/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/16/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.004/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/18/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/14/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/13/2025CTNMContineum TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.003/11/2025SAGESage TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$5.003/7/2025CGEMCullinan TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$38.00 ➝ $35.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K21,493.36N/AN/A$2.75 per share1.93CGEMCullinan TherapeuticsN/AN/AN/AN/A$10.61 per shareN/ACTNMContineum Therapeutics$50M2.29$0.70 per share6.35($3.72) per share-1.19SAGESage Therapeutics$47.40M8.75N/AN/A$7.56 per share0.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.26N/AN/AN/A-199,076.92%-55.81%-50.60%8/6/2025 (Estimated)CGEMCullinan Therapeutics-$153.16M-$2.91N/AN/AN/AN/A-26.54%-25.32%8/14/2025 (Estimated)CTNMContineum Therapeutics$22.72M-$1.97N/AN/AN/AN/A-49.92%-20.52%8/12/2025 (Estimated)SAGESage Therapeutics-$400.67M-$5.80N/AN/AN/A-971.50%-68.18%-60.84%7/30/2025 (Estimated)Latest CTNM, ALT, SAGE, and CGEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CTNMContineum Therapeutics-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million5/8/2025Q1 2025CGEMCullinan Therapeutics-$0.78-$0.74+$0.04-$0.74N/AN/A4/29/2025Q1 2025SAGESage Therapeutics-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/ACTNMContineum TherapeuticsN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.8716.87CGEMCullinan TherapeuticsN/A24.4624.46CTNMContineum TherapeuticsN/A37.0637.06SAGESage TherapeuticsN/A7.427.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%CGEMCullinan Therapeutics86.31%CTNMContineum TherapeuticsN/ASAGESage Therapeutics99.22%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%CGEMCullinan Therapeutics7.16%CTNMContineum Therapeutics11.30%SAGESage Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million68.21 millionOptionableCGEMCullinan Therapeutics3059.02 million54.69 millionOptionableCTNMContineum Therapeutics3125.87 millionN/AN/ASAGESage Therapeutics69062.62 million58.10 millionOptionableCTNM, ALT, SAGE, and CGEM HeadlinesRecent News About These CompaniesSage Therapeutics (NASDAQ:SAGE) Upgraded at Wall Street ZenJune 2 at 2:41 AM | americanbankingnews.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the InvestigationJune 1 at 10:00 AM | accessnewswire.comToronto Dominion Bank Makes New $742,000 Investment in Sage Therapeutics, Inc. (NASDAQ:SAGE)June 1 at 4:32 AM | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Stock Rating Upgraded by Wall Street ZenJune 1 at 12:24 AM | marketbeat.comVoloridge Investment Management LLC Cuts Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 31 at 4:10 AM | marketbeat.comWhy Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?May 29, 2025 | zacks.comBronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities InvestigationMay 29, 2025 | accessnewswire.comMan Group plc Takes Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 28, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the InvestigationMay 27, 2025 | accessnewswire.com136,723 Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE) Purchased by Toronto Dominion BankMay 27, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Purchased by Millennium Management LLCMay 27, 2025 | marketbeat.comSage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationMay 25, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to ConnectMay 22, 2025 | accessnewswire.comLazard Asset Management LLC Buys New Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 22, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Buys 114,173 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)May 21, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities InvestigationMay 20, 2025 | accessnewswire.comNeuromodulation: rewiring healthcare?May 19, 2025 | msn.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of "Hold" from BrokeragesMay 19, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach OutMay 18, 2025 | accessnewswire.comRTW Investments LP Lowers Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 18, 2025 | marketbeat.comJane Street Group LLC Raises Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueUnitedHealth Insiders Double Down: Is UNH Stock a Value Play?By Jeffrey Neal Johnson | May 19, 2025View UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?3 High-Paying Dividend Stocks That Still Have Safe PayoutsBy Chris Markoch | May 27, 2025View 3 High-Paying Dividend Stocks That Still Have Safe Payouts3 Trades Members of Congress Are Making Right NowBy Chris Markoch | May 23, 2025View 3 Trades Members of Congress Are Making Right NowWill Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?By Gabriel Osorio-Mazilli | May 22, 2025View Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?CTNM, ALT, SAGE, and CGEM Company DescriptionsAltimmune NASDAQ:ALT$5.30 -0.13 (-2.39%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$5.34 +0.04 (+0.75%) As of 05:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Cullinan Therapeutics NASDAQ:CGEM$8.75 +0.10 (+1.16%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$8.75 0.00 (0.00%) As of 06/2/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Contineum Therapeutics NASDAQ:CTNM$4.43 +0.77 (+21.04%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$4.44 +0.01 (+0.14%) As of 06/2/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Sage Therapeutics NASDAQ:SAGE$6.62 +0.16 (+2.48%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$6.60 -0.01 (-0.23%) As of 06/2/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern 3 Stocks With 3% to 9% Yields Just Raised Dividends Again MarketBeat Week in Review – 05/26 - 05/30 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
